SCHEMBL25972149

SCHEMBL25972149

CC(=O)c1nn(Cc2ccccc2)c(Cl)c1C=O

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.51
MEN1 O00255 2/20 0.51
ALDH1A1 P00352 8/20 0.44
LMNA P02545 6/20 0.44
NPSR1 Q6W5P4 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
KDM4E B2RXH2 3/20 0.43
HTT P42858 1/20 0.43
POLB P06746 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.41
TSHR P16473 1/20 0.40
GRN P28799 1/20 0.40
SORT1 Q99523 1/20 0.40
MAPT P10636 1/20 0.40
THRB P10828 1/20 0.40
HPGD P15428 1/20 0.40
TDP1 Q9NUW8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25972443 0.88 KMT2A (0.49) KMT2AMEN1LMNASMN1; SMN2NPC1
SCHEMBL28991674 0.85 SMN1; SMN2 (0.53) KMT2AMEN1ALDH1A1LMNASMN1; SMN2
SCHEMBL25972156 0.83 KMT2A (0.46) KMT2AMEN1ALDH1A1LMNASMN1; SMN2
SCHEMBL20477344 0.83 CYP19A1 (0.54) KMT2AMEN1ALDH1A1LMNANPSR1
SCHEMBL25972166 0.83 KDM4E (0.38) KMT2AMEN1ALDH1A1LMNANPSR1
SCHEMBL25972158 0.81 KMT2A (0.49) KMT2AMEN1ALDH1A1LMNASMN1; SMN2
SCHEMBL25972449 0.81 SMN1; SMN2 (0.45) KMT2AMEN1ALDH1A1LMNASMN1; SMN2
SCHEMBL964648 0.80 KMT2A (0.60) KMT2AMEN1ALDH1A1LMNANPSR1
SCHEMBL25972119 0.79 GAA (0.36) KMT2AMEN1ALDH1A1KDM4E
SCHEMBL25972285 0.79 GRIN1 (0.39) ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11718612-B2 Inhibitors of receptor interacting protein kinase I for the treatment of disease BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2023-08-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718612-B2 Inhibitors of receptor interacting protein kinase I for the treatment of disease RIPK1, RIPK2, RIPK4 KMT2A 3766/4885MEN1 4212/4885ALDH1A1 4554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.